Combination treatment may affect IOP results.

Article

Using diclofenac sodium 0.1% and latanoprost 0.005% simultaneously could affect intraocular pressure (IOP) in glaucoma patients

Using diclofenac sodium 0.1% and latanoprost 0.005% simultaneously could affect intraocular pressure (IOP) in glaucoma patients, according to a study published in the Journal of Glaucoma.

Dr Rana Sorkhabi et al., Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Iran, studied 22 patients with bilateral primary open angle glaucoma. Each patient was administered latanoprost for 4 weeks.

The patients were given topical diclofenac sodium in one eye and hydroxypropyl methyl cellulose was given in the other. This was completed 4 times a day for a fortnight. IOP was measured 2 weeks after treatment and 2 weeks after stopping other ophthalmic treatments.

The findings revealed additional administration of diclofenac sodium raised mean IOP from 15.73±1.75 to 17.32±2.23 mmHg. Two weeks after patients stopped using additional solutions, IOP was reduced. The control group did not show any significant difference in mean IOP. When co-administrating diclofenac sodium and latanoprost, the possibility of interference should be considered.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.